Reviews/Statins/Lower achieved LDL cholesterol is associated with greater cardiovascular event reduction
· ST-SEC-03 · v2
Across many study types, people who end up with lower LDL cholesterol, or who drop their LDL the most, tend to have fewer heart attacks, strokes and related events. Two trials that randomly assigned patients to a lower LDL goal or a stronger LDL-lowering drug saw fewer events in the lower-LDL group [10], [12], and this matters because randomisation removes most of the ways patients could differ. Analyses that measure events per unit of LDL drop show a steady, graded relationship [9], [15], and it keeps going even down to very low LDL levels [8], [14]. Large real-world patient records point the same way [17], [21]. The main caution is that in most studies 'achieved LDL' reflects who the patient is and how reliably they took treatment, not LDL alone, so the association is clearer than the proof that LDL itself is the sole cause.
Randomisation to a lower LDL target [10] (HR 0.67) and to a strong LDL-lowering agent [12] (HR 0.85) both cut events. Per-unit analyses give a dose-response: HR 0.75 per 1 mmol/L with bempedoic acid [9] and 24% lower MACE per 39 mg/dL with alirocumab [15]. The gradient is monotonic down to <20 mg/dL [8] and shows no attenuation below 1 mmol/L [14]. Large cohorts corroborate, with larger LDL reduction tracking lower hazard across all outcomes [17] and sub-optimal response raising CVD risk (HR 1.17) [21], and a mediation analysis attributes a 20% lower MACE risk to a 30% lower LDL [2]. The contested point: The division is over interpretation, not direction: in most studies 'achieved LDL' is a non-randomised post-treatment variable [3], [5], [8], [17], [21], so confounding by indication and the healthy-adherer effect could inflate the gradient, and [20] shows adherence itself lowers both LDL and coronary risk. The panel treated this as qualifying causal attribution while leaving the association itself intact, because the two randomised designs [10], [12] isolate the lowering effect.
All 27 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Statins, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
In most included studies 'achieved LDL' is a non-randomized, post-treatment variable, so the gradient is open to confounding by indication and the healthy-adherer effect — patients who reach low LDL are systematically healthier/more adherent. This applies to [8], [5], [3], [17] and [21].
Adherence may be the true driver: [20] shows the same adherence that lowers LDL also lowers CHD risk and is associated with unrelated outcomes (cataract, iron-deficiency anaemia), marking patient behaviour rather than a pure LDL effect.
Where it remains uncertain. In most studies achieved LDL is a post-treatment, non-randomised variable [5], [8], [17], [21], and adherence alone predicts both LDL reduction and coronary risk [20], so confounding qualifies causal attribution.
Aleatory
Some dose-response estimates rest on modest event counts, e.g. 104 MACE in the pooled ODYSSEY analysis [15], widening confidence intervals.
Epistemic
The usable corpus is dominated by secondary-prevention/established-ASCVD populations ([5], [8], [10], [12], [17]); achieved-LDL dose-response in primary prevention is not directly established here.
The load-bearing papers from a corpus of 27, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Associates lower achieved LDL with lower MACE and estimates most of drug effect mediated via LDL.
“A 30% lower time-updated average LDL was associated with 20% lower risk of primary MACE (hazard ratio 0·80, 95% CI 0·68-0·94)”
Panel auditInternal validity: medium · scope of inference: People with HIV on stable ART at low-to-moderate ASCVD risk with minimally elevated LDL.Key limitations: observational LDL-event link within trial · wide mediation CI · HIV-specific population
Demonstrates a graded association persisting to the lowest achieved LDL-C levels.
“There was a monotonic relationship between lower achieved LDL-C levels-down to very low levels <20 mg/dL-and a lower risk of the primary efficacy end point”
Panel auditInternal validity: medium · scope of inference: Patients with stable atherosclerotic cardiovascular disease on evolocumab in long-term follow-up.Key limitations: observational achieved-LDL comparison · residual confounding · stable ASCVD only
Shows event reduction scales per unit of LDL lowering, consistent across agents.
“When normalized per 1 mmol/L reduction in LDL-C, the HR was 0.75 (95% CI: 0.63-0.90), comparable to the rate ratio of 0.78 reported for statins in the CTTC meta-analysis”
Panel auditInternal validity: high · scope of inference: Statin-intolerant patients with or at high risk for cardiovascular disease.Key limitations: per-reduction not achieved-level framing · statin-intolerant population · post hoc normalisation
Post-PCI cohort reinforcing graded association of LDL reduction with outcomes.
“greater relative LDL-C reduction was associated with a significantly lower risk of the primary outcome in a nonlinear pattern (overall P = 0.0001; nonlinearity P = 0.0007)”
Panel auditInternal validity: low · scope of inference: Real-world post-PCI secondary-prevention patients at one Japanese tertiary centre.Key limitations: single centre retrospective · confounding by indication · modest sample
4 of 27 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Multiple independent primary designs across drug classes and populations converge on a graded lower-LDL/fewer-events association with no credible contrary primary evidence in the included corpus.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Primary-prevention achieved-LDL dose-response. The claim is stated without population qualification, yet the usable corpus is dominated by secondary-prevention/ASCVD populations ([5], [8], [10], [12], [17]). The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A randomised lower-versus-higher LDL target trial in a primary-prevention cohort with event endpoints.
Open question: Does the lower-achieved-LDL/fewer-events association hold with the same gradient in primary prevention? Why it is still open: Primary-prevention achieved-LDL dose-response is thin in this corpus, which is dominated by secondary-prevention populations ([5], [8], [10], [12], [17]).
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 26 Oct 2026 · protocol v0.19